DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dyne Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$15.23+0.98 (+6.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -33.4% | -55.7% | |
| Return on assets | – | -32.1% | -47.5% | |
| Current ratio | – | 31.83 | 22.25 | |
| Diluted shares | – | 14M | – |
Where the cash went
Fiscal 2021 to 2025, five years combined
Dyne Therapeutics generated $1.16B from operations and spent $11.71M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.16B
Used
$11.71M
Capital expenditure$11.71M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$446.21M
- Cash generatingOperating cash flow above zero-$403.21M
- Return on assets improvedROA up on the prior year-192.3% → -64.6%
- Earnings backed by cashOperating cash flow above net income-$403.21M vs -$446.21M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose15.60 → 22.25
- No dilutionShare count did not rise– → –
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –